Altogether, these findings suggest that 1 mechanism of enhanced efficacy of the combination of DR-18 and anti–CTLA-4 is the limitation of DR-18-induced Treg expansion by anti–CTLA-4, although additional studies are needed to unequivocally define the precise mechanisms, including the role of the tumor draining lymph node. Here, CTLA4 is linked to neoplasm.